Feed 688105.SS
68

Nanjing Vazyme Biotech Co., Ltd. 688105.SS · SHH

¥23.99 -2.20% (-¥0.54)

Summary

17 / 100 · Bulios Score

What speaks for it

  • Out of every 100 CNY of revenue, 16 CNY is left as free cash.
  • The price moves less than the market (beta 0.68).

What to watch

  • Revenue fell by 27% a year over the last 3 years.
  • The company made a loss over the last 12 months.
  • Repaying its net debt would take 6.2 years of operating profit.
  • The share price is above the Bulios Fair Price.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks expensive

Price against the Bulios Fair Price

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

The company made a loss over the last 12 months, so there is no profit to set the price against.

Valuation in detail

Is it growing?

It is shrinking

Revenue (CNY)

Diluted EPS (CNY)

  • Analyst estimate

Revenue fell by 2.5% a year over 5 years. Over the last 3 years it fell by 27% a year.

Growth in detail

Does it make money?

Poorly

Over the last 12 months it made a loss of ¥9.14M.

Profitability in detail

Is it financially healthy?

Yes

Repaying all its debt would take 2.9 years of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

Small, at risk
Yield
2.04%
Raised in a row
1 year

You receive ¥0.50 per share a year. The payout is more than the company can comfortably cover.

Dividends in detail

What do analysts expect?

No coverage

No analyst covers this stock.

Analysts in detail

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.